As noted in the Supplementary Table S2, the chemotherapy regimens in the trials included lacked targeted therapies such as trastuzumab or pertuzumab for HER2-positive disease, and regimens such as 3M (mitomycin C, mitoxantrone, methotrexate) or 2M (mitoxantrone, methotrexate) used in Makris et al. [5] are no longer first-line treatments in breast cancer. Here, ERBB2 is linked to breast carcinoma.